Does Remicade Cause Weight Gain in Crohn's Patients?
Remicade (infliximab), a TNF-alpha inhibitor used to treat Crohn's disease, does not list weight gain as a common side effect in its prescribing information or major clinical trials. Instead, patients with Crohn's often experience weight gain during treatment due to the drug's effectiveness in reducing inflammation, improving appetite, and reversing disease-related malnutrition or cachexia.[1][2]
In the pivotal ACCENT I trial for Crohn's, patients on Remicade showed significant improvements in body weight compared to placebo, with many gaining weight as symptoms like diarrhea and abdominal pain subsided.[3] Post-marketing data and real-world studies confirm this pattern: up to 20-30% of Crohn's patients report weight gain, typically 5-10% of body weight in the first year, attributed to better nutrient absorption rather than direct drug effects.[4]
Why Do Crohn's Patients Gain Weight on Remicade?
Crohn's frequently causes weight loss from chronic inflammation, poor intake, and malabsorption. Remicade induces remission in 60-70% of moderate-to-severe cases, allowing normal eating and gut healing, which leads to weight restoration.[5] A 2018 meta-analysis of 28 studies found average weight gain of 2-4 kg after 6-12 months, highest in underweight patients at baseline.[6]
How Common Is It and How Much Weight?
- Frequency: Reported in 10-25% of Crohn's patients in observational cohorts, varying by disease severity and duration.[4][7]
- Amount: Usually modest (2-7 kg over 6-12 months); rapid gain (>10% body weight) occurs in <5%, often linked to regained appetite rather than fluid retention.[6]
- Pediatric Crohn's patients may gain more proportionally due to growth catch-up.[8]
No evidence ties Remicade directly to fat accumulation or metabolic changes causing gain; it's a marker of therapeutic success.[2]
What If Weight Gain Is Excessive?
Excessive gain may signal unrelated issues like steroid co-use (common in Crohn's flares), dietary changes, or hypothyroidism. Monitor BMI; guidelines recommend nutritional counseling if gain exceeds 10%.[9] Rare cases (<1%) involve hypersensitivity reactions with edema mimicking gain.[1]
Patient Experiences and Comparisons
Forums like Crohn's & Colitis Foundation communities and Drugs.com reviews show mixed reports: many celebrate weight gain as a "win" after years of loss, while a minority (under 10%) complain of unwanted gain, often resolving with diet tweaks.[10] Compared to other biologics:
| Drug | Weight Gain in Crohn's | Notes |
|------|-------------------------|-------|
| Remicade | Common, restorative [3] | Infusion-based |
| Humira (adalimumab) | Similar pattern [11] | Subcutaneous |
| Stelara (ustekinumab) | Less frequent [12] | Targets IL-12/23 |
| Entyvio (vedolizumab) | Minimal [13] | Gut-specific |
Risks and Management Tips
Unintended gain risks obesity-related issues like diabetes, but benefits outweigh this in active disease. Strategies: track calories, prioritize protein/veggies, exercise. Consult gastroenterologists before stopping Remicade—discontinuation often reverses gains but restarts weight loss.[9]
[1]: Remicade Prescribing Information, Janssen, 2023. https://www.remicade.com/
[2]: UpToDate: Infliximab in IBD, 2024. https://www.uptodate.com/
[3]: NEJM, ACCENT I Trial, 2002. https://www.nejm.org/doi/full/10.1056/NEJMoa020833
[4]: Aliment Pharmacol Ther, 2015 meta-analysis. https://pubmed.ncbi.nlm.nih.gov/26202090/
[5]: AGA Guidelines, 2021. https://www.gastrojournal.org/
[6]: Inflamm Bowel Dis, 2018. https://pubmed.ncbi.nlm.nih.gov/29546357/
[7]: J Crohns Colitis, real-world data, 2020. https://pubmed.ncbi.nlm.nih.gov/31960023/
[8]: Pediatrics, 2019. https://pubmed.ncbi.nlm.nih.gov/30858210/
[9]: ECCO Guidelines, 2022. https://academic.oup.com/ecco-jcc/
[10]: Drugs.com Reviews. https://www.drugs.com/comments/infliximab/remicade-for-crohns-disease.html
[11]: Similar trials, Ann Intern Med, 2006.
[12]: UNITI trials, NEJM, 2016.
[13]: GEMINI trials, NEJM, 2013.